Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Bristol-Myers’ Dual Oral Hepatitis C Regimen Debuts in Japan
September 4, 2014
- Prostate Cancer Drug Zytiga Now Available in Japan: Janssen
September 4, 2014
- GSK’s 2013 Payments to Health Professionals in Japan at 10 Billion Yen
September 4, 2014
- Torii’s Sublingual Hay Fever Drug to Hit Market in October
September 4, 2014
- Ichiro Yoshimoto to Become New President of CMIC
September 4, 2014
- CMIC Holdings to Boost Domestic CSO Business, Converting Its Subsidiary to JV with UDG Healthcare
September 4, 2014
- Drug Price Settlement Rate Might Hit 70% in September: Wholesaler Exec
September 3, 2014
- Daiichi Sankyo Espha to Launch AG Versions of Cravit after NHI Price Listing in December
September 3, 2014
- Ono Launches Opdivo, Making Full-Fledged Entry to Oncology Field
September 3, 2014
- Eisai Books 18.7 Billion Yen in Payments to Medical Institutions in FY2013
September 2, 2014
- Astellas’ FY2013 Funding to Medical Institutions Totals 18.7 Billion Yen
September 2, 2014
- 33.2 Billion Yen Paid to Medical Institutions in FY2013: Daiichi Sankyo
September 2, 2014
- Takeda’s Payments to Health Professionals Down 30% in FY2013
September 2, 2014
- Kyowa Kirin Initiates PIIb Study of Regpara Successor in Japan
September 2, 2014
- Kyowa Kirin Merges Ethics Office into CSR Promotion Dept., Following Improper Involvement of Its Employees in Clinical Study
September 2, 2014
- 10-Year Epidemiology Study Finds No Significant Increase in Bladder Cancer Risk from Actos: Takeda
September 1, 2014
- Novartis Pharma Submits Improvement Plan, Notifies of Over 2,500 Unreported Serious ADRs
September 1, 2014
- Mundipharma Begins PII Trial on Antifolate Pralatrexate in Japan
September 1, 2014
- Daiichi Sankyo Forms Sales Agreement with Kaketsuken for Hepatitis B Vaccine
September 1, 2014
- Fujifilm Starts PI Study of Its Anticancer Agent FF-10501 for Hematological Malignancy in US
September 1, 2014
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…